Status:
COMPLETED
Effects of Espresso on Platelet Aggregability in Patients with Coronary Artery Disease
Lead Sponsor:
University of Sao Paulo
Collaborating Sponsors:
Fundação de Amparo à Pesquisa do Estado de São Paulo
Conditions:
Coronary Artery Disease
Eligibility:
All Genders
20-80 years
Phase:
NA
Brief Summary
Discovered thousands of years ago, coffee is among the most consumed beverages in the world. The relationship between coffee and cardiovascular risk, more specifically coronary artery disease, is cont...
Detailed Description
30 patients with coronary artery disease (proven by previous coronary angiography) will be selected at the Heart Institute (InCor USP) for the study. Patients will be instructed to abstain from caffei...
Eligibility Criteria
Inclusion
- Age 20 to 80 years;
- Coronary artery disease documented by coronary angiography;
- Use of aspirin 100mg.
Exclusion
- Serum creatinine dosage \> 2.5 mg/dl;
- Hemoglobin \<12 g/% for men and \<11 g/% for women;
- Platelets \<100,000 or \>400,000/mm3;
- Leukocytosis \>12,000/mm3;
- Fasting glycemia \>126mg/dl;
- Aspartate aminotransferase (AST) and/or Alanine aminotransferase (ALT) with values above the upper limits of normality;
- Consumption of more than 30 grams of alcohol per day;
- Active smoking or ex-smoking for less than 2 years;
- Use of P2Y12 inhibitor;
- Ventricular dysfunction (left ventricular ejection fraction \<45%).
Key Trial Info
Start Date :
September 1 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 25 2024
Estimated Enrollment :
29 Patients enrolled
Trial Details
Trial ID
NCT04827251
Start Date
September 1 2022
End Date
November 25 2024
Last Update
February 13 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Heart Institute (InCor) / University of São Paulo
São Paulo, São Paulo, Brazil, 05403-000